Search Results
Your search for Chase Doyle ,Chase Doyle matches 550 pages
Showing 451 - 500Expert Point of View: Julie Margenthaler, MD, FACS
JULIE MARGENTHALER, MD, FACS, a breast surgeon at Washington University School of Medicine and American Society of Breast Surgeons Communications Committee Chair, highlighted the importance of exploring clinical endpoints outside of a survival advantage. “While numerous studies have shown the...
Regular Mammograms Linked to Less Aggressive Treatment in Patients With Breast Cancer
A STUDY evaluating the impact of breast cancer screening has shown that the benefits of regular mammograms extend well beyond reduced mortality. According to data presented at the American Society of Breast Surgeons (ASBrS) 2018 Annual Meeting, women with breast cancer who underwent regular...
Expert Point of View: Sarah Blair, MD
SARAH BLAIR, MD, a breast surgeon at the University of California San Diego, noted that lymphedema remains a significant clinical problem, although the rates of lymphedema are decreasing, as fewer full axillary node dissections are performed. “This study utilizes bioimpedance spectroscopy, a...
Early Detection and Intervention Reduce Breast Cancer–Related Lymphedema
A NEW STUDY has found that early detection along with a simple intervention can be highly effective in preventing breast cancer–related lymphedema for at-risk women. According to data presented at the 2018 Annual Meeting of the American Society of Breast Surgeons,1 82% of women identified at an...
Expert Point of View: Judy C. Boughey, MD
JUDY C. BOUGHEY, MD, a breast surgeon and clinical and translational researcher at the Mayo Clinic, Rochester, Minnesota, said the two studies highlight the importance of discussing genetic testing with patients who are diagnosed with breast cancer. “With the advances in panel testing for...
Studies Challenge Relevance of Genetic Testing Guidelines for Breast Cancer
NEW RESEARCH suggests that current genetic testing guidelines for breast cancer are far too restrictive, excluding nearly half of high-risk patients. According to a pair of studies presented at the 2018 American Society of Breast Surgeons (ASBrS) Annual Meeting, women with breast cancer who did not ...
Expert Point of View: Carla S. Fisher, MD
CARLA S. FISHER, MD, Associate Professor of Surgery at Indiana University School of Medicine, Indianapolis, underscored the importance of these data in informing treatment decisions given the difficult trade-off patients can face. “By analyzing a large group of patients treated in the modern era, ...
Recurrence Rates After Lumpectomy Significantly Improved in Patients Receiving ‘Modern-Era’ Therapy
A STUDY OF local recurrence rates following lumpectomy has shown significant improvement in patients receiving modern, multimodal therapies, suggesting breast-conserving surgery may be an option for more patients with breast cancer, according to data presented at the 2018 American Society of Breast ...
Circulating Tumor DNA May Guide Treatment Intensity in Advanced HPV-Associated Head and Neck Cancers
A MULTI-INSTITUTIONAL analysis of circulating tumor DNA extracted from the plasma of patients has shown that human papillomavirus type 16 (HPV16) DNA is detectable in the majority of cases of favorable-risk HPV-associated oropharyngeal squamous cell carcinoma and may be a clinically useful...
Lower-Dose Radiation in HPV-Positive Head and Neck Cancers After Induction Chemotherapy
The results of a phase II clinical trial suggest that patients with head and neck cancers associated with the human papillomavirus (HPV) may receive significantly lower doses of radiation safely and effectively after response to induction chemotherapy.1 These findings from the OPTIMA study,...
Expert Point of View: Young Jun Kim, MD, PhD
YOUNG JUN KIM, MD, PhD, Co-Leader of the Translational Research and Interventional Oncology Research Program at Vanderbilt-Ingram Cancer Center, in Nashville, called the research “very important work.” “This is very close to clinical relevance because no special test is required right now,” said...
Intratumor Heterogeneity of Head and Neck Cancers May Have Therapeutic Implications
A RETROSPECTIVE STUDY of The Cancer Genome Atlas may have therapy-specific implications for patients with head and neck squamous cell carcinoma, according to data presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium.1 This first analysis of the relationship between intratumor...
Panitumumab-Based Contrast Agent May Enhance Head and Neck Cancer Surgery
AN OPTICAL CONTRAST agent composed of panitumumab (Vectibix), a humanized anti–epidermal growth factor receptor (EGFR) monoclonal antibody, conjugated to the near-infrared fluorescent dye IRDye800, may aid in the real-time detection and surgical resection of squamous cell carcinoma, according to...
Expert Point of View: Young Jun Kim, MD, PhD
YOUNG JUN KIM, MD, PhD, Co-Leader of the Translational Research and Interventional Oncology Research Program at Vanderbilt-Ingram Cancer Center in Nashville, was more guarded in his interpretation of the data, particularly focusing on the lack of clinical improvement in the combination cohort that ...
Phase II Study Shows Durvalumab Active in Patients With Recurrent or Metastatic Head and Neck Cancer
IN A POPULATION of heavily pretreated patients with recurrent or metastatic head and neck cancer and low or negative programmed cell death ligand 1 (PD-L1) expression, durvalumab (Imfinzi) monotherapy demonstrated an overall response rate of 9.2%, consistent with that of single-agent programmed...
Expert Point of View: Francis P. Worden, MD
THE MODERATOR of the session, Francis P. Worden, MD, a medical oncologist at the University of Michigan Health System Comprehensive Cancer Center in Ann Arbor, called the study thought-provoking despite its retrospective nature. “The data from this study are thought provoking,” said Dr. Worden....
Delays in Radiation Therapy After Surgery for Head and Neck Cancer Linked to Decreased Survival
DELAYS IN RADIATION THERAPY after surgery for head and neck cancer were associated with decreased survival in a large population of U.S. patients, according to data presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium and reported online recently in JAMA Otolaryngology Head & ...
Expert Point of View: Malcolm K. Brenner, MD, PhD
Discussant for the abstract, Malcolm K. Brenner, MD, PhD, of Baylor College of Medicine Texas Children’s Hospital, underscored the need to make chimeric antigen receptor (CAR) T-cell therapy both safer and more effective. He also noted that overcoming antigen loss with multiple CARs is the next...
Trivalent CAR T-Cell Design May Enhance Antitumor Efficacy in Acute Lymphoblastic Leukemia
A novel approach to chimeric antigen receptor (CAR) T-cell therapy seems to effectively target acute lymphoblastic leukemia (ALL) cells with varying antigen profiles and may help to overcome antigen escape, seen with CD19-targeted therapy. According to data presented at the 2018 ASCO-SITC Clinical...
Expert Point of View: Ravindra Uppaluri, MD, PhD
Discussant of the abstract, Ravindra Uppaluri, MD, PhD, Chief of the Division of Otolaryngology in the Department of Surgery at the Brigham and Women’s Hospital and Director of Head and Neck Surgical Oncology at the Dana-Farber Cancer Institute, said this research underscores the complex biology...
Testing for PD-L1 Amplification May Help Predict Response to Immune Checkpoint Blockade in Solid Tumors
Analysis of more than 100,000 patients with cancer for gene CD274 (programmed cell death ligand 1 [PD-L1]) amplification may have implications for treatment with immune checkpoint blockade. Although shown to be rare in solid tumors, copy number alterations in PD-L1 genes were present in more than...
Expert Point of View: Ezra Cohen, MD, PhD
Discussant for the abstract, Ezra Cohen, MD, PhD, of the University of California, San Diego, pointed out that although this subgroup may be responsive to checkpoint inhibition, it may not necessarily be anti–programmed cell death protein 1 (anti–PD-1) therapy. “There are emerging data suggesting...
Targetable Immune Biology Found in Some Patients With Early-Stage Prostate Cancer
Although immunotherapy has improved outcomes across a growing number of cancers, its success in unselected cases of prostate cancer has been limited. According to data presented at the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium, however, investigators have identified a group of patients with ...
Expert Point of View: Francis P. Worden, MD
The moderator of the session, Francis P. Worden, MD, a medical oncologist at the University of Michigan Health System Comprehensive Cancer Center, in Ann Arbor, highlighted the number of poorly differentiated carcinomas, which is higher than reported in other previous, large studies. “In previous...
Cabozantinib Therapy Shows Activity in Differentiated Thyroid Cancer
Cabozantinib (Cometriq) has demonstrated significant activity in the first-line setting for radioiodine-refractory differentiated thyroid carcinoma, according to data from a single-site phase II trial presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium.1 Treatment with...
Expression of Endogenous Retroviruses May Explain Response to Immune Checkpoint Therapy in Renal Cell Cancer
RESULTS OF a new study suggest that expression of endogenous retroviruses may be associated with activation of immune checkpoint pathways in renal cell cancer.1 According to data presented at the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium, abnormal expression of endogenous retroviruses may...
EXPERT POINT OF VIEW: Deborah J.L. Wong, MD, PhD
DISCUSSANT FOR THIS abstract, Deborah J.L. Wong, MD, PhD, of the David Geffen School of Medicine at the University of California, highlighted the preclinical rationale, as well as in vitro and in vivo data, supporting the potential benefit of poly (ADP-ribose) polymerase (PARP) inhibitors in...
Combination PARP and PD-1 Inhibition Shows Antitumor Activity in Advanced Malignancies
IN A PHASE I trial of patients with advanced solid tumors, the combination of pamiparib (BGB-290), a selective poly (ADP-ribose) polymerase (PARP) inhibitor, and tislelizumab (BGB-A317), an agent targeting the programmed cell death protein 1 (PD-1) receptor, was well tolerated while demonstrating...
Responses Reported With CAR T-Cell Therapy in High-Risk NHL
LISOCABTAGENE MARALEUCEL (Liso-cel; JCAR017), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy with defined composition, has shown “potent and durable” responses in poor-prognosis patients with relapsed or refractory aggressive non-Hodgkin lymphoma (NHL) in a phase I trial.1 According ...
EXPERT POINT OF VIEW: Ravindra Uppaluri, MD, PhD
“This is a large, well-done study,” said Ravindra Uppaluri, MD, PhD, Chief of the Division of Otolaryngology in the Department of Surgery at the Brigham and Women’s Hospital and Director of Head and Neck Surgical Oncology at Dana-Farber Cancer Institute, who underscored the small number of...
Combination Radiotherapy and Immunotherapy Appears Safe and Clinically Active in Advanced Solid Tumors
Results from the first and largest prospective trial to determine the safety of multisite ablative stereotactic body radiotherapy (SBRT) in combination with anti–programmed cell death protein 1 (anti–PD-1) immunotherapy pembrolizumab (Keytruda) suggest the combination regimen may improve outcomes...
Expert Point of View: Eduardo Bruera, MD, FAAHPM
Eduardo Bruera, MD, FAAHPM, Medical Director, Department of Supportive Care Center, The University of Texas MD Anderson Cancer Center, in Houston, called the dyadic intervention “highly innovative.” “We all talk about movement, exercise, and the importance of physical activity for our patients,...
Dyadic Yoga Program for Patients With Lung Cancer and Their Caregivers May Optimize Treatment Response
Yoga therapy delivered to patients with lung cancer and their caregivers together appears to be a feasible and beneficial supportive care strategy. According to data presented at the 2017 Palliative and Supportive Care in Oncology Symposium,1 the dyadic intervention resulted in a clinically and...
Caring for the Frail, Older Patient With Cancer: Four Practical Approaches
Cancer may be a disease of aging, but data suggest that older patients with cancer are undertreated, especially with respect to chemotherapy. One analysis showed that approximately 40% of patients in their 70s—and 60% of patients in their 80s—do not receive adjuvant therapy after surgery for colon...
Expert Point of View: Eduardo Bruera, MD, FAAHPM
Eduardo Bruera, MD, FAAHPM, Medical Director, Department of Supportive Care Center, The University of Texas MD Anderson Cancer Center, Houston, underscored the study’s potential to influence clinical care decisions. “The emergency department is a ‘hard hat’ area of care where bad things happen and ...
‘Triple Threat’ Conditions May Predict Mortality in Patients With Cancer Presenting to Emergency Departments
Dyspnea, delirium, and poor performance—so-called “triple threat” conditions—are known to predict short survival in palliative care. According to data presented at the 2017 Palliative and Supportive Care in Oncology Symposium,1 however, the presence of at least two of these symptoms in patients...
Concurrent Palliative Care: Recommendations From the ASCO Clinical Practice Guideline
Updated in 2016, the ASCO clinical practice guideline on the integration of palliative care into standard oncology care provides evidence-based recommendations to oncology clinicians, patients, family and friend caregivers, and palliative care specialists about providing high-quality care for...
Palliative Care Intervention Reduces Total Health-Care Costs in Patients With Advanced Cancer
A matched case-controlled study among Medicare beneficiaries with metastatic lung, colorectal, breast, and prostate cancers has found that palliative care consultation significantly reduced total health-care costs following intervention. According to data presented at the 2017 Palliative and...
Digital Palliative Care Curriculum Improves Knowledge, Skills, and Opioid Prescribing Behavior
A new electronic curriculum delivered via e-mail with push technology may provide an efficient, cost-effective solution to the shortage of palliative care faculty serving the nation’s oncology fellowship programs. According to data presented at the 2017 Palliative and Supportive Care in Oncology...
Early Integrated Palliative Care Improves Patient Coping Strategies, Quality of Life, and Symptoms of Depression
A new study has shed light on how palliative care interventions may improve patient outcomes. According to data presented at the 2017 Palliative and Supportive Care in Oncology Symposium,1 patients with incurable cancer who received early integrated palliative care had an increased use of active...
Clinical Relevance of Minimal Residual Disease Monitoring Limited in Acute Myeloid Leukemia
Although a majority of major cancer centers may test for minimal residual disease (MRD), a recent survey conducted by researchers at Moffitt Cancer Center, Tampa, Florida, suggests most oncologists remain uncertain about what to do with the results. At the National Comprehensive Cancer Network®...
New Options for the Management of Hodgkin Lymphoma
With the vast majority of patients cured with primary therapy, classical Hodgkin lymphoma is largely a success story. For the 10% to 20% of patients who either relapse or are refractory to front-line therapy, the disease can still be fatal. At the National Comprehensive Cancer Network® (NCCN®) 12th ...
Sequencing Therapy in Chronic Lymphocytic Leukemia
Although the indications to initiate treatment for chronic lymphocytic leukemia (CLL) have not changed, determining the optimal first-line treatment and sequence of therapies once treatment has begun remain challenges for providers. At the National Comprehensive Cancer Network® (NCCN®) 12th Annual...
Life After Treatment: Managing Lymphoma Survivors
According to Surveillance, Epidemiology, and End Results (SEER) data, patients with Hodgkin lymphoma and non-Hodgkin lymphoma (NHL) have 5-year survival rates of 86% and 71%, respectively.1 Although the increased number of survivors is welcome proof of the success of new treatment regimens, it also ...
Management of Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients
The treatment paradigm for multiple myeloma has changed dramatically in the past decade with the availability of several efficacious agents in various drug classes. At the National Comprehensive Cancer Network® (NCCN®) 13th Annual Congress: Hematologic Malignancies™, Shaji K. Kumar, MD, Professor...
Immunotherapeutic Approaches for B-Cell Acute Lymphocytic Leukemia
New therapeutic agents for acute lymphocytic leukemia (ALL) have led to dramatic improvement in remission rates, but questions concerning the proper sequencing and combination of these agents remain. At the National Comprehensive Cancer Network® (NCCN®) 13th Annual Congress: Hematologic...
Blinatumomab ‘Takes a BiTE’ Out of Acute Lymphoblastic Leukemia
An investigational immunotherapy is improving outcomes in difficult-to-treat acute lymphoblastic leukemia (ALL) and showing promise in other cancers, as well. Blinatumomab (Blincyto), the first U.S. Food and Drug Administration (FDA)-approved bispecific T-cell engager (BiTE), has demonstrated...
Immune System Is Shaping the Future of Multiple Myeloma Treatment
From immunomodulatory agents and proteasome inhibitors to steroids, alkylators, and antibodies, recent years have witnessed an explosion of drug approvals for multiple myeloma. The challenge now, said Amrita Krishnan, MD, FACP, is figuring out how to incorporate them all, particularly in the...
Treating Human Immunodeficiency Virus–Related Lymphoma
Alexandra Levine, MD, MACP, is Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, Duarte, California, and has been on the front lines of the AIDS epidemic from the beginning—before the disease even had a name. Dr. Levine spoke with The ASCO Post about ...
Treatment of Diffuse Large B-Cell Lymphoma Continues to Evolve
Although the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) has improved with R-CHOP—the addition of rituximab (Rituxan) to the cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy regimen—one-third of patients still relapse after therapy, and patients with the ...
